Finance

Beta
Lists
4RY:FRA
Akeso Inc
€11.16
-5.10%
(-0.60) 1D
Jun 3, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 4RY...
Open
€11.06
High
€11.33
Low
€11.06
Mkt. cap
90.09B
Avg. vol.
116.00
Volume
1.00
52-wk high
€19.30
52-wk low
€8.20
No. of employees
4K
Open
€11.06
High
€11.33
Low
€11.06
Mkt. cap
90.09B
Avg. vol.
116.00
Volume
1.00
52-wk high
€19.30
52-wk low
€8.20
No. of employees
4K
News stories
From sources across the web
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong. It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
About Akeso Inc
CEOMichelle Xia | Michelle Xia
Employees3.76K
FoundedMar 19, 2012
Headquarters-
SectorBiotechnology
Websiteakesobio.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
705.77M
705.77M
822.37M
822.37M
Cost of goods sold
153.29M
153.29M
191.35M
191.35M
Cost of revenue
153.29M
153.29M
191.35M
191.35M
Research and development expenses
365.62M
365.62M
421.91M
421.91M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
401.95M
401.95M
464.36M
464.36M
Operating expense
797.32M
797.32M
883.23M
883.23M
Total operating expenses
950.61M
950.61M
1.07B
1.07B
Operating income
-244.84M
-244.84M
-252.21M
-252.21M
Other non operating income
9.48M
9.48M
29.10M
29.10M
EBT including unusual items
-293.95M
-293.95M
-276.45M
-276.45M
EBT excluding unusual items
-297.71M
-297.71M
-276.19M
-276.19M
Income tax expense
192.50K
192.50K
-192.50K
-192.50K
Effective tax rate
-0.07%
-0.07%
0.07%
0.07%
Other operating expenses
29.74M
29.74M
-3.04M
-3.04M
Net income
-285.04M
-285.04M
-271.47M
-271.47M
Net profit margin
-40.39%
-40.39%
-33.01%
-33.01%
Earnings per share
-
-
-
-
Interest and investment income
65.18M
65.18M
84.42M
84.42M
Interest expense
-31.68M
-31.68M
-33.81M
-33.81M
Net interest expenses
33.50M
33.50M
50.61M
50.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-188.45M
-188.45M
-187.68M
-187.68M
Gain or loss from assets sale
-
-
-1.00K
-1.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer